LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.6 -2.7

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.6

Max

3.79

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.11% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

162M

1.2B

Ouverture précédente

6.3

Clôture précédente

3.6

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 déc. 2025, 23:48 UTC

Principaux Mouvements du Marché

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8 déc. 2025, 23:44 UTC

Market Talk

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8 déc. 2025, 23:42 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8 déc. 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 déc. 2025, 23:13 UTC

Market Talk

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8 déc. 2025, 23:09 UTC

Acquisitions, Fusions, Rachats

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8 déc. 2025, 22:46 UTC

Market Talk

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8 déc. 2025, 22:01 UTC

Market Talk

Miners Poised to Do Well in 2026 -- Market Talk

8 déc. 2025, 22:00 UTC

Acquisitions, Fusions, Rachats

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8 déc. 2025, 22:00 UTC

Acquisitions, Fusions, Rachats

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8 déc. 2025, 22:00 UTC

Acquisitions, Fusions, Rachats

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8 déc. 2025, 22:00 UTC

Acquisitions, Fusions, Rachats

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8 déc. 2025, 21:51 UTC

Market Talk

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8 déc. 2025, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

8 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 déc. 2025, 21:38 UTC

Acquisitions, Fusions, Rachats

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8 déc. 2025, 21:38 UTC

Acquisitions, Fusions, Rachats

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8 déc. 2025, 21:36 UTC

Market Talk

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8 déc. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8 déc. 2025, 21:12 UTC

Acquisitions, Fusions, Rachats

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 déc. 2025, 21:08 UTC

Market Talk

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8 déc. 2025, 20:38 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8 déc. 2025, 20:26 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 déc. 2025, 20:18 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8 déc. 2025, 20:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8 déc. 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8 déc. 2025, 20:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 déc. 2025, 20:05 UTC

Market Talk

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8 déc. 2025, 20:01 UTC

Market Talk

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

8.11% hausse

Prévisions sur 12 Mois

Moyen 4 USD  8.11%

Haut 4 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat